| Nov 11 |
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
|
| Nov 7 |
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
|
| Nov 5 |
High Growth Tech Stocks To Watch In November 2024
|
| Nov 5 |
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
|
| Nov 4 |
SpringWorks Therapeutics Merits A Speculative Buy
|
| Nov 4 |
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth Plans
|
| Oct 22 |
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
|
| Oct 9 |
SpringWorks Therapeutics Inc (SWTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Oct 7 |
High Growth Tech Stocks in the United States for October 2024
|
| Sep 19 |
Even though SpringWorks Therapeutics (NASDAQ:SWTX) has lost US$229m market cap in last 7 days, shareholders are still up 49% over 5 years
|
